Booming Boston Scientific Preps Return of Lotus TAVR Device
Boston Scientific's chief executive says the company intends to continue its momentum achieving top-line growth across all business segments, and is preparing to re-introduce its Lotus device into the burgeoning transcatheter aortic valve replacement (TAVR) market in 2017’s fourth quarter.
Massachusetts-based Boston Scientific reported sales of $2.16 billion during the first quarter, up 10 percent from the prior year, and the sixth straight quarter of 10 percent or greater operational revenue growth. Net income reached $290 million, up 43 percent from $202 million one year ago.
Massachusetts-based Boston Scientific reported sales of $2.16 billion during the first quarter, up 10 percent from the prior year, and the sixth straight quarter of 10 percent or greater operational revenue growth. Net income reached $290 million, up 43 percent from $202 million one year ago.